Clinical Trial Update: Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial from AstraZeneca evaluating a KRAS G12D-targeted TCR-T cell therapy in adults with unresectable, advanced, or metastatic solid tumors, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Endometrial Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• KRAS G12D-targeted TCR-T cell therapy (KRAS G12D-targeted TCR-T cell therapy)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer, Colorectal Carcinoma | Phase 1 | Status: RECRUITING